Most People Carrying the Ankylosing Spondylitis Gene Never Develop It
HLA-B27 is present in the large majority of people with ankylosing spondylitis, and in millions who will never have a symptom. What the genetics of spondyloarthritis actually shows, and why diagnosis still rests on a rheumatologist rather than a genotype.
A person in their twenties has back pain that is worse in the morning and eases once they start moving. It takes years to get a name for it — diagnostic delay in ankylosing spondylitis is still commonly measured in years, not months.
When the name arrives, it usually comes with a genetic test. Ankylosing spondylitis has one of the strongest genetic associations in common disease: the great majority of people diagnosed with it carry a particular immune-system variant, HLA-B27.
Run that association backwards and it collapses. Most people who carry HLA-B27 never develop ankylosing spondylitis — the large majority live entire lives without a symptom.
Both statements are true simultaneously. Understanding why is most of what there is to understand about genetic risk.
Sensitive, not specific
A test can be good at appearing in cases and still be bad at identifying who has the disease, if the variant is common and the disease is rare.
GenePlaza's own app documentation puts it plainly: current diagnosis of spondyloarthritis and its ankylosing spondylitis subtype rests on the HLA-B27 antigen, "which is not necessarily sensitive nor specific for the disease."
In practice, HLA-B27 is one input into a clinical picture — inflammatory back pain, imaging, inflammatory markers, response to treatment, family history — assembled by a rheumatologist. It is not a diagnosis on its own, and a positive result in someone without symptoms usually means nothing at all.
What the rest of the genetics shows
HLA-B27 is the largest signal but far from the only one. An exome-wide study of 5,040 ankylosing spondylitis patients and 21,133 controls identified a novel association at CDKAL1, alongside suggestive associations at several other loci (Cortes et al., npj Genomic Medicine, 2016).
The striking part of that work is what the genes have in common. Much of the non-HLA genetic architecture of ankylosing spondylitis is shared with inflammatory bowel disease — the same pathways, repeatedly. That overlap is not a coincidence of statistics; gut inflammation is common in spondyloarthritis patients, and the genetics and the clinic point the same way.
A broader review of the pathogenesis covers how these findings fit together, including the IL-23/IL-17 axis that several effective drugs now target (Brown et al., Nature Reviews Rheumatology, 2016, PMID: 26439405).
There is also early work on whether genotype predicts treatment response in spondyloarthritis — a systematic review found the evidence still limited and inconsistent (Ciccacci et al., Frontiers in Genetics, 2021, PMID: 34354741). Worth knowing before anyone offers to pick your biologic by DNA.
If you have back pain and a positive result
The important message is the unglamorous one. Inflammatory back pain that is worse in the morning, improves with movement, and persists for months is worth a doctor's attention regardless of your genotype — and diagnostic delay in ankylosing spondylitis is measured in years, which is the real problem worth solving.
A genetic result is not a diagnosis, and a negative one does not rule the condition out. If this is a live question for you, the route is a GP or rheumatologist.
What the app reports
Spondyloarthritis Insights implements findings from the published spondyloarthritis literature against your genotype and summarises the relevant papers. As with every GenePlaza app, the output tells you where you would have fallen in the original study population had you taken part in it - not that you personally carry raised or lowered risk of anything.
Its documentation states the limits explicitly: the application "is not a diagnosis, a prediction, or a predisposition score" and "is an implementation of the findings in referenced papers for research purposes only. There might be conflicting results from different studies."
That is an honest description of what genetic literature for a complex autoimmune disease can currently offer, and a good deal more honest than most things sold in this space.